Alerts will be sent to your verified email
Verify Email
BROOKS
|
Brooks Laboratories
|
Albert David
|
Medicamen Biotech
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-23.88 % | 11.47 % | 8.49 % |
|
5yr average Equity Multiplier
|
1.78 | 1.63 | 1.47 |
|
5yr Average Asset Turnover Ratio
|
0.6 | 0.62 | 0.58 |
|
5yr Avg Net Profit Margin
|
-23.79 % | 11.31 % | 10.0 % |
|
Price to Book
|
4.6 | 1.19 | 2.26 |
|
P/E
|
0.0 | 74.08 | 50.58 |
|
5yr Avg Cash Conversion Cycle
|
-10.34 Days | -77.77 Days | 13.14 Days |
|
Inventory Days
|
93.5 Days | 47.91 Days | 66.66 Days |
|
Days Receivable
|
66.75 Days | 27.87 Days | 122.66 Days |
|
Days Payable
|
179.8 Days | 140.35 Days | 257.34 Days |
|
5yr Average Interest Coverage Ratio
|
-11.84 | 93.73 | 10.36 |
|
5yr Avg ROCE
|
-15.03 % | 14.69 % | 12.12 % |
|
5yr Avg Operating Profit Margin
|
-13.23 % | 9.55 % | 16.84 % |
|
5 yr average Debt to Equity
|
0.21 | 0.02 | 0.14 |
|
5yr CAGR Net Profit
|
0.22 % | -4.92 % | -6.51 % |
|
5yr Average Return on Assets
|
-14.62 % | 7.03 % | 5.75 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
52.62 % | 62.24 % | 40.46 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-13.79 % | 0.25 % | -3.14 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
9.9 % | 0.0 | 0.0 |
|
Brooks Laboratories
|
Albert David
|
Medicamen Biotech
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|